Cellectar biosciences' iopofosine i 131 exceeds primary endpoint in waldenstrom's macroglobulinemia pivotal study with 78% of major response patients remaining progression free at 18 months

56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40% dual-class refractory (btki and rituximab) florham park, n.j., july 23, 2024 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced positive results from its clover wam pivotal study evaluating iopofosine i 131, a potential first-in-class, targeted radiotherapeutic candidate for the treatment of relapsed/refractory waldenstrom's macroglobulinemia (wm) patients that received at least two prior lines of therapy, including bruton tyrosine kinase inhibitors (btki's).
CLRB Ratings Summary
CLRB Quant Ranking